News Releases

REDWOOD CITY, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) --  Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will participate in the 33 rd Annual Piper Sandler Healthcare Conference being held from

REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming virtual investor conferences.

REDWOOD CITY, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the third quarter ended September 30, 2021.

REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2021 after the close of trading on Tuesday,

Blue Cross Blue Shield of Michigan and Horizon Blue Cross Blue Shield of New Jersey Issue Coverage Policies Providing Coverage for Treatment with the Zephyr® Valve REDWOOD CITY, Calif. --(BUSINESS WIRE)--Sep. 21, 2021-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally

REDWOOD CITY, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) today announced the company will be participating in fireside chats at two upcoming virtual investor conferences. Pulmonx management is scheduled to participate in the 2021 Virtual Wells Fargo

Positive Coverage Policy Gives Additional 34   Million People Access to Treatment with the Zephyr® Valve, a Minimally Invasive Treatment Option REDWOOD CITY, Calif. --(BUSINESS WIRE)--Aug. 20, 2021-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments

REDWOOD CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the second quarter ended June 30, 2021.

Alissa Hsu Lynch and Tiffany Sullivan join the Pulmonx Board of Directors REDWOOD CITY, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG), a global leader in minimally invasive treatments for severe lung disease, welcomes Alissa Hsu Lynch and Tiffany Sullivan to its Board

REDWOOD CITY, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 41 st Annual Growth